Get the Stockscreener App
1.52
0.00%
0.00
Okyo Pharma Limited stock is traded at $1.52, with a volume of 99,573.
It is up +0.00% in the last 24 hours and up +6.29% over the past month.
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
See More
Previous Close:
$1.52
Open:
$1.53
24h Volume:
99,573
Relative Volume:
1.04
Market Cap:
$79.77M
Revenue:
-
Net Income/Loss:
$-4.61M
P/E Ratio:
-12.12
EPS:
-0.1254
Net Cash Flow:
$-3.10M
1W Performance:
-3.18%
1M Performance:
+6.29%
6M Performance:
-13.14%
1Y Performance:
-42.64%
1-Day Range:
$1.50
$1.58
1-Week Range:
$1.49
$1.60
52-Week Range:
$1.3401
$3.20
Okyo Pharma Limited Stock (OKYO) Company Profile
Compare OKYO vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OKYO
Okyo Pharma Limited
|
1.52 | 79.77M | 0 | -4.61M | -3.10M | -0.1254 |
VRTX
Vertex Pharmaceuticals Inc
|
515.89 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
806.79 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.45 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
211.83 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.81 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Okyo Pharma Limited Stock (OKYO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-20-26 | Initiated | Piper Sandler | Overweight |
| Dec-08-25 | Initiated | B. Riley Securities | Buy |
Okyo Pharma Limited Stock (OKYO) Latest News
Short Interest in OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Expands By 223.4% - MarketBeat
OKYO Pharma (NASDAQ: OKYO) updates 20-F to add clawback policy exhibit - stocktitan.net
OKYO Pharma (OKYO) director buys 5,000 shares in open market - Stock Titan
OKYO Pharma (OKYO) Slips 2.6% to $1.49, Testing Key Support at $1.42Late Stage Breakouts - dars.gov.et
Price to sales forward of OKYO Pharma Limited – NASDAQ:OKYO - tradingview.com
OKYO Pharma (OKYO) Expected to Post Quarterly Earnings on Monday - MarketBeat
Form 4 OKYO Pharma Ltd For: 29 July By Investing.com - Investing.com Canada
OKYO Pharma CSO buys shares - Proactive financial news
OKYO Pharma CSO purchases additional shares at $1.49 By Investing.com - Investing.com Nigeria
OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer - The Manila Times
OKYO Pharma (Nasdaq: OKYO) CSO boosts stake, plans Phase 3 NCP trial - Stock Titan
OKYO Pharma scientist's holdings reach 20,030 shares after purchase - Stock Titan
OKYO Pharma CSO purchases additional shares at $1.49 - Investing.com
OKYO Pharma Ltd (OKYO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
OKYO Pharma to participate in BTIG Biotechnology Conference 2026 - Proactive financial news
OKYO Pharma Ltd (OKYO) Cash Flow - TradingKey
OKYO Pharma (NASDAQ:OKYO) Is In A Good Position To Deliver On Growth Plans - simplywall.st
OKYO Pharma to Participate in BTIG Biotechnology Conference 2026 - Quiver Quantitative
OKYO Pharma (Nasdaq: OKYO) plans Phase 3 NCP trial, joins BTIG conference - Stock Titan
OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026 - GlobeNewswire
OKYO Pharma Ltd (OKYO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
OKYO Pharma Ltd (OKYO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
OKYO Pharma Ltd (OKYO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
OKYO Pharma Ltd (OKYO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
OKYO Pharma Ltd (OKYO) Institutional Confidence - TradingKey
OKYO Pharma Ltd (OKYO) Valuation: PE, PB & Fair Value Analysis - TradingKey
OKYO Pharma Limited Revenue Breakdown – GETTEX:OK11 - TradingView
OKYO|OKYO Pharma Ltd|Price:1.530|Chg%:+0.020 - TradingKey
TradingKey - TradingKey
OKYO Pharma outlines path to phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain - Ophthalmology Times Europe
Form 4 OKYO Pharma Ltd For: 24 July By Investing.com - Investing.com South Africa
OKYO Pharma Declines Slightly, Tests Support Near $1.39 as Biotech Sector Faces PressureIndex Put Call - dars.gov.et
OKYO Pharma (OKYO) grants 3,500 shares to chief development officer - Stock Titan
OKYO Pharma CEO Robert Dempsey Acquires 15,000 Shares at $1.54 Ahead of Phase 3 Trial Launch - Kalkine Media
OKYO Pharma director buys 5,000 shares at $1.48, increasing his stake to 35,201 shares. - Pluang
OKYO Pharma Director John Brancaccio Purchases 5,000 Shares on Nasdaq - Quiver Quantitative
OKYO Pharma (Nasdaq: OKYO) director ups stake with 5,000-share purchase - Stock Titan
OKYO Pharma Announces Purchase of Shares by Director - GlobeNewswire
OKYO Pharma CEO purchases 15,000 shares at $1.54 each - Investing.com
OKYO Pharma CEO purchases 15,000 shares at $1.54 each By Investing.com - Investing.com South Africa
OKYO Pharma Announces Purchase of Shares by Chief Executive Officer - The Manila Times
OKYO Pharma (Nasdaq: OKYO) CEO purchases 15,000 company shares - Stock Titan
OKYO Pharma says CEO purchased 15,000 shares - Proactive financial news
OKYO Pharma executive purchases 3,500 shares at $1.40 each By Investing.com - Investing.com Australia
OKYO Pharma grants CMO 20,000 common shares | OKYO Insider Trading - Stock Titan
OKYO Pharma Chairman Boosts Stake to Over 20% Ahead of Phase 3 Trial - TipRanks
OKYO Pharma Chairman buys 22,500 shares, raisin... - Pluang
OKYO Pharma (Nasdaq: OKYO) chair buys more shares, now owns 20.55% - Stock Titan
OKYO Pharma LTD - Via Ritzau
OKYO Pharma executive purchases 3,500 shares at $1.40 each - Investing.com India
OKYO Pharma CMO purchases 20,000 shares at $1.40 each By Investing.com - Investing.com South Africa
Okyo Pharma Limited Stock (OKYO) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.00%
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):